Barclays Boosts Organon & Co. (NYSE:OGN) Price Target to $8.00

Organon & Co. (NYSE:OGN) had its target price increased by analysts at Barclays from $7.50 to $8.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “underweight” rating on the stock. Barclays‘s price objective suggests a potential downside of 1.28% from the stock’s current price.

Other equities research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. dropped their price target on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research report on Tuesday, November 11th. Morgan Stanley decreased their price objective on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 11th. Piper Sandler downgraded shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price target for the company. in a research note on Monday, October 27th. Zacks Research lowered shares of Organon & Co. from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Wall Street Zen cut shares of Organon & Co. from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. One analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and five have issued a Sell rating to the stock. According to MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and an average target price of $8.50.

Organon & Co. Price Performance

Shares of NYSE:OGN opened at $8.10 on Tuesday. Organon & Co. has a twelve month low of $6.18 and a twelve month high of $16.18. The company has a current ratio of 1.75, a quick ratio of 1.20 and a debt-to-equity ratio of 9.69. The company has a market cap of $2.11 billion, a PE ratio of 11.39, a price-to-earnings-growth ratio of 0.73 and a beta of 0.58. The company’s 50 day moving average is $7.94 and its 200 day moving average is $8.51.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.73 by ($0.10). The business had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.52 billion. Organon & Co. had a return on equity of 123.06% and a net margin of 3.01%.The company’s revenue for the quarter was down 5.3% on a year-over-year basis. During the same period last year, the business earned $0.90 EPS. On average, sell-side analysts forecast that Organon & Co. will post 3.68 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Organon & Co. by 2.7% in the fourth quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock valued at $264,690,000 after purchasing an additional 987,979 shares during the last quarter. State Street Corp raised its stake in shares of Organon & Co. by 2.8% in the 4th quarter. State Street Corp now owns 9,597,761 shares of the company’s stock valued at $68,816,000 after purchasing an additional 262,185 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Organon & Co. by 105.2% during the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after purchasing an additional 4,394,814 shares during the last quarter. Private Management Group Inc. grew its stake in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after purchasing an additional 1,204,979 shares in the last quarter. Finally, UBS Group AG raised its stake in Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after buying an additional 1,527,492 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.